| [1] |
Lim H, Devesa SS, Sosa JA, et al.
Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMAJAMA, 2017, 317(13): 1338-1348.
doi: 10.1001/jama.2017.2719 |
| [2] |
丁勇, 马庆杰, 王任飞, 等.
分化型甲状腺癌术后131I治疗前评估专家共识[J]. 中国癌症杂志中国癌症杂志, 2019, 29(10): 832-840.
doi: 10.19401/j.cnki.1007-3639.2019.10.011 Ding Y, Ma QJ, Wang RF, et al. Expert consensus on pre-treatment evaluation of 131I of differentiated thyroid cancer after surgery[J]. China OncolChina Oncol, 2019, 29(10): 832-840. doi: 10.19401/j.cnki.1007-3639.2019.10.011 |
| [3] |
National Cancer Institute. SEER cancer statistics review[EB/OL].(2019-03-03)[2021-10-11]. https://seer.cancer.gov/statfacts/html/thyro.html. |
| [4] |
Haugen BR, Alexander EK, Bible KC, et al.
2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020 |
| [5] |
Spencer CA.
Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2011, 96(12): 3615-3627.
doi: 10.1210/jc.2011-1740 |
| [6] |
Chiovato L, Latrofa F, Braverman LE, et al.
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens[J]. Ann Intern MedAnn Intern Med, 2003, 139(5 Pt 1): 346-351.
doi: 10.7326/0003-4819-139-5_part_1-200309020-00010 |
| [7] |
Spencer CA, Takeuchi M, Kazarosyan M, et al.
Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 1998, 83(4): 1121-1127.
doi: 10.1210/jcem.83.4.4683 |
| [8] |
Latrofa F, Ricci D, Grasso L, et al.
Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2008, 93(2): 591-596.
doi: 10.1210/jc.2007-1199 |
| [9] |
Spencer C, Fatemi S.
Thyroglobulin antibody (TgAb) methods-strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol MetabBest Pract Res Clin Endocrinol Metab, 2013, 27(5): 701-712.
doi: 10.1016/j.beem.2013.07.003 |
| [10] |
Jo K, Kim MH, Ha J, et al.
Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer[J]. Clin Endocrinol (Oxf)Clin Endocrinol (Oxf), 2017, 87(3): 292-299.
doi: 10.1111/cen.13367 |
| [11] |
Fröhlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases[J/OL]. Front Immunol, 2017, 8: 521[2021-10-11]. https://www.frontiersin.org/articles/10.3389/fimmu.2017.00521/full. DOI: 10.3389/fimmu.2017.00521. |
| [12] |
Qin J, Yu ZQ, Guan HX, et al.
High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma[J]. Dis MarkersDis Markers, 2015, 2015: 648670-.
doi: 10.1155/2015/648670 |
| [13] |
Wassner AJ, Vecchia MD, Jarolim P, et al.
Prevalence and significance of thyroglobulin antibodies in pediatric thyroid cancer[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2017, 102(9): 3146-3153.
doi: 10.1210/jc.2017-00286 |
| [14] |
国家儿童医学中心, 国家儿童肿瘤监测中心, 中华医学会小儿外科学分会, 等.
中国儿童甲状腺结节及分化型甲状腺癌专家共识[J]. 中华实用儿科临床杂志中华实用儿科临床杂志, 2020, 35(20): 1521-1530.
doi: 10.3760/cma.j.cn101070-20200804-01291 National Center for Children's Health, National Children's Cancer Surveillance Center, Pediatric Surgery Branch of Chinese Medical Association, et al. Expert consensus on thyroid nodules and differentiated thyroid cancer for Chinese children[J]. Chin J Appl Clin PediatrChin J Appl Clin Pediatr, 2020, 35(20): 1521-1530. doi: 10.3760/cma.j.cn101070-20200804-01291 |
| [15] |
Ernaga-Lorea A, Hernández-Morhain MC, Anda-Apiñániz E, et al.
Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma[J]. Clin Transl OncolClin Transl Oncol, 2018, 20(6): 740-744.
doi: 10.1007/s12094-017-1782-3 |
| [16] |
Li C, Yu WB, Fan JC, et al. Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers[J/OL]. Oncotarget, 2016, 7(31): 49930−49938[2021-10-11]. https://www.oncotarget.com/article/10236/text. DOI: 10.18632/oncotarget.10236. |
| [17] |
So YK, Kim MJ, Kim S, et al.
Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location[J]. Int J SurgInt J Surg, 2018, 50: 94-103.
doi: 10.1016/j.ijsu.2017.12.029 |
| [18] |
Schlumberger MJ.
Papillary and follicular thyroid carcinoma[J]. N Engl J MedN Engl J Med, 1998, 338(5): 297-306.
doi: 10.1056/NEJM199801293380506 |
| [19] |
Shen CT, Zhang XY, Qiu ZL, et al.
Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?[J]. EndocrineEndocrine, 2017, 58(1): 176-183.
doi: 10.1007/s12020-017-1401-7 |
| [20] |
Lee ZJO, Eslick GD, Edirimanne S.
Investigating antithyroglobulin antibody as a prognostic marker for differentiated thyroid cancer: a meta-analysis and systematic review[J]. ThyroidThyroid, 2020, 30(11): 1601-1612.
doi: 10.1089/thy.2019.0368 |
| [21] |
Giagourta I, Evangelopoulou C, Papaioannou G, et al.
Autoimmune thyroiditis in benign and malignant thyroid nodules: 16-year results[J]. Head NeckHead Neck, 2014, 36(4): 531-535.
doi: 10.1002/hed.23331 |
| [22] |
Xing MZ.
Prognostic utility of BRAF mutation in papillary thyroid cancer[J]. Mol Cell EndocrinolMol Cell Endocrinol, 2010, 321(1): 86-93.
doi: 10.1016/j.mce.2009.10.012 |
| [23] |
Li W, Ming H, Sun DY, et al.
The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma[J]. Pathol Res PractPathol Res Pract, 2017, 213(3): 183-188.
doi: 10.1016/j.prp.2016.12.022 |
| [24] |
Ehlers M, Schott M.
Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?[J]. Trends Endocrinol MetabTrends Endocrinol Metab, 2014, 25(12): 656-664.
doi: 10.1016/j.tem.2014.09.001 |
| [25] |
Borrello MG, Degl'Innocenti D, Pierotti MA.
Inflammation and cancer: the oncogene-driven connection[J]. Cancer LettCancer Lett, 2008, 267(2): 262-270.
doi: 10.1016/j.canlet.2008.03.060 |
| [26] |
Zhang N, Liang J, Lin YS. Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb[J/OL]. Oncotarget, 2017, 8(57): 97407−97415[2021-10-11]. https://www.oncotarget.com/article/22129/text. DOI: 10.18632/oncotarget.22129. |
| [27] |
Morbelli S, Ferrarazzo G, Pomposelli E, et al.
Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications[J]. J Endocrinol InvestJ Endocrinol Invest, 2017, 40(4): 417-424.
doi: 10.1007/s40618-016-0578-6 |
| [28] |
张娜, 梁军, 林岩松.
甲状腺球蛋白抗体对甲状腺乳头状癌131I清甲疗效的影响[J]. 中国癌症杂志中国癌症杂志, 2017, 27(6): 476-481.
doi: 10.19401/j.cnki.1007-3639.2017.06.013 Zhang N, Liang J, Lin YS. The impact of thyroglobulin antibody on efficacy of 131I ablation in patients with papillary thyroid carcinoma[J]. China OncolChina Oncol, 2017, 27(6): 476-481. doi: 10.19401/j.cnki.1007-3639.2017.06.013 |
| [29] |
Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al.
The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane[J]. Endocr Relat CancerEndocr Relat Cancer, 2006, 13(1): 257-269.
doi: 10.1677/erc.1.01119 |
| [30] |
Verburg FA, Luster M, Cupini C, et al.
Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement[J]. ThyroidThyroid, 2013, 23(10): 1211-1225.
doi: 10.1089/thy.2012.0606 |
| [31] |
南楠, 鲜于志群, 赵明, 等.
甲状腺球蛋白抗体与分化型甲状腺癌131I治疗效果的关系研究[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2021, 45(9): 545-551.
doi: 10.3760/cma.j.cn121381-202007044-00094 Nan N, Xianyu ZQ, Zhao M, et al. Studies on the relationship between thyroglobulin antibody and the therapeutic effect of 131I in patients with differentiated thyroid carcinoma[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2021, 45(9): 545-551. doi: 10.3760/cma.j.cn121381-202007044-00094 |
| [32] |
Bueno F, Falcone MGG, Peñaloza MA, et al.
Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer[J]. EndocrineEndocrine, 2020, 67(2): 387-396.
doi: 10.1007/s12020-019-02112-7 |
| [33] |
刘日信, 曾凤伟, 李建芳, 等.
分化型甲状腺癌131I治疗后早期TgAb变化幅度与疗效的关系[J]. 临床与病理杂志临床与病理杂志, 2019, 39(6): 1215-1219.
doi: 10.3978/j.issn.2095-6959.2019.06.010 Liu RX, Zeng FW, Li JF, et al. Early change of TgAb and the therapeutic efficiency in differentiated thyroid carcinoma patients after 131I treatment[J]. J Clin Pathol ResJ Clin Pathol Res, 2019, 39(6): 1215-1219. doi: 10.3978/j.issn.2095-6959.2019.06.010 |
| [34] |
Kim WG, Yoon JH, Kim WB, et al.
Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2008, 93(12): 4683-4689.
doi: 10.1210/jc.2008-0962 |
| [35] |
Tsushima Y, Miyauchi A, Ito Y, et al.
Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients[J]. Endocr JEndocr J, 2013, 60(7): 871-876.
doi: 10.1507/endocrj.ej12-0410 |
| [36] |
Rosario PW, Carvalho M, Mourão GF, et al.
Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography[J]. ThyroidThyroid, 2016, 26(4): 525-531.
doi: 10.1089/thy.2015.0445 |
| [37] |
Yin N, Sherman SI, Pak Y, et al.
The de novo detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence[J]. ThyroidThyroid, 2020, 30(10): 1490-1495.
doi: 10.1089/thy.2019.0791 |
| [38] |
李田军, 林岩松, 梁军, 等.
甲状腺球蛋白抗体在甲状腺乳头状癌131I治疗后的转阴时间及其影响因素[J]. 中国医学科学院学报中国医学科学院学报, 2012, 34(3): 258-261.
doi: 10.3881/j.issn.1000-503X.2012.03.013 Li TJ, Lin YS, Liang J, et al. Time to disappearance of thyroglobulin antibodies and influencing factors in patients with papillary thyroid carcinoma[J]. Acta Acad Med SinActa Acad Med Sin, 2012, 34(3): 258-261. doi: 10.3881/j.issn.1000-503X.2012.03.013 |
| [39] |
Song E, Ahn J, Oh HS, et al.
Time trends of thyroglobulin antibody in ablated papillary thyroid carcinoma patients: can we predict the rate of negative conversion?[J]. Oral OncolOral Oncol, 2019, 91: 29-34.
doi: 10.1016/j.oraloncology.2019.02.022 |
| [40] |
Matrone A, Latrofa F, Torregrossa L, et al.
Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without 131I ablation[J]. ThyroidThyroid, 2018, 28(7): 871-879.
doi: 10.1089/thy.2018.0080 |
| [41] |
丛慧, 梁军, 李方, 等.
分化型甲状腺癌治疗后TgAb变化趋势及其影响因素[J]. 中国医学科学院学报中国医学科学院学报, 2015, 37(1): 61-65.
doi: 10.3881/j.issn.1000-503X.2015.01.011 Cong H, Liang J, Li F, et al. Changes in thyroglobulin antibodies after treatment of differentiated thyroid cancer and its influencing factors[J]. Acta Acad Med SinActa Acad Med Sin, 2015, 37(1): 61-65. doi: 10.3881/j.issn.1000-503X.2015.01.011 |
| [42] |
张腾, 宋丽萍, 赵腾, 等.
淋巴结转移对分化型甲状腺癌手术及131I治疗后血清甲状腺球蛋白抗体转阴的影响[J]. 中国医学科学院学报中国医学科学院学报, 2017, 39(4): 539-543.
doi: 10.3881/j.issn.1000-503X.2017.04.013 Zhang T, Song LP, Zhao T, et al. Effect of lymph node metastasis on change of positive thyroglobulin antibody in differentiated thyroid carcinoma after initial treatment[J]. Acta Acad Med SinActa Acad Med Sin, 2017, 39(4): 539-543. doi: 10.3881/j.issn.1000-503X.2017.04.013 |
| [43] |
丛慧, 李慧, 梁军, 等.
硒制剂对甲状腺球蛋白抗体阳性分化型甲状腺癌甲状腺球蛋白抗体水平的影响[J]. 中国医学科学院学报中国医学科学院学报, 2015, 37(5): 591-595.
doi: 10.3881/j.issn.1000-503X.2015.05.017 Cong H, Li H, Liang J, et al. Effect of selenious yeast tablets on the thyroglobulin antibody level in thyroglobulin antibody-positive patients with differentiated thyroid cancer[J]. Acta Acad Med SinActa Acad Med Sin, 2015, 37(5): 591-595. doi: 10.3881/j.issn.1000-503X.2015.05.017 |